找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Aggressive Lymphomas; Georg Lenz,Gilles Salles Book 2019 Springer Nature Switzerland AG 2019 Malignant Lymphoma.Therapy Malignant Lymphoma

[復制鏈接]
樓主: subcutaneous
11#
發(fā)表于 2025-3-23 11:04:27 | 只看該作者
M. Castrillón-Santana,Q. C. Vuongways (STAT3, NF-κB) in multiple PTCL entities. In general, cutaneous T-cell lymphomas sow distinct genetic and molecular landscape compared to the nodal diseases. However, there are marked differences in their frequency, with some quite distinct to specific entities (e.g., IDH2. mutation in angioimm
12#
發(fā)表于 2025-3-23 14:54:44 | 只看該作者
13#
發(fā)表于 2025-3-23 19:55:39 | 只看該作者
Lectures on Inflationary Cosmologyetermining prognosis. With standardisation of PET acquisition and the use of more sophisticated software, total metabolic tumour volume (TMTV) calculations are becoming feasible. TMTV has the potential to provide the single most efficient and relevant means of informing clinicians and patients of th
14#
發(fā)表于 2025-3-23 23:46:51 | 只看該作者
Dark Matter and Sakharov Oscillations being modified to elicit increased immune activity or to bring chemotherapy or a radioactive isotope closer to the tumor cells. Patients who relapse after R-containing first-line therapy (Gisselbrecht et al., J Clin Oncol 28(27):4184–4190, 2010) showed their dismal prognosis; the recently published
15#
發(fā)表于 2025-3-24 05:49:34 | 只看該作者
2197-9766 interested in lymphoma, including clinicians from various medical specialties, biologists, pathologists, radiologists and nuclear medicine specialist, as well as students..978-3-030-00362-3Series ISSN 2197-9766 Series E-ISSN 2197-9774
16#
發(fā)表于 2025-3-24 08:23:24 | 只看該作者
17#
發(fā)表于 2025-3-24 11:41:46 | 只看該作者
Pathology and Molecular Pathogenesis of DLBCL and Related Entitiesatures, with over ten entities recognized in the updated WHO classification of hematopoietic and lymphoid tissues. Among them, DLBCL not otherwise specified (NOS) represents the most common diagnosis, accounting for 25–30% of all B cell lymphoma cases. In recent years, significant progress has been
18#
發(fā)表于 2025-3-24 18:51:42 | 只看該作者
Pathology and Molecular Pathogenesis of Burkitt Lymphoma and Lymphoblastic Lymphomafor approximately 4–5% of all non-Hodgkin lymphomas in Western countries. These B-cell neoplasms were frequently grouped together in the past, due to their fast-growing clinical behavior, related to a short doubling time, and their frequent presentation as acute leukemia. Burkitt leukemia was former
19#
發(fā)表于 2025-3-24 19:47:18 | 只看該作者
Pathology and Molecular Pathogenesis of T-Cell Lymphomaorld Health Organization has recognized at least 29 PTCL entities, with few additional provisional entities. However, a large subset cannot be classified using current methodology and are designated as PTCL, not otherwise specified (PTCL-NOS). The molecular and genomic landscape of the major PTCL su
20#
發(fā)表于 2025-3-24 23:44:57 | 只看該作者
Standard of Care in First-Line Therapy of DLBCL of patients are cured with frontline chemoimmunotherapy, with most relapses occurring within the first 2 years from diagnosis. While some of the patients with relapsed disease can be salvaged with aggressive chemotherapy and transplant approaches, the majority of patients who relapse after modern f
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-24 04:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
罗甸县| 荣昌县| 富蕴县| 宁强县| 沂水县| 贡觉县| 英吉沙县| 秀山| 太康县| 新乡县| 沁阳市| 东海县| 韶山市| 甘泉县| 年辖:市辖区| 叶城县| 崇礼县| 西藏| 团风县| 青田县| 文山县| 邵东县| 商洛市| 黔西县| 永吉县| 太康县| 思南县| 和政县| 通化市| 云霄县| 梧州市| 怀仁县| 新泰市| 合川市| 万山特区| 长顺县| 桂林市| 田林县| 万州区| 洛阳市| 江阴市|